Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
<p>Abstract</p> <p>Background</p> <p>In recent years, maintenance chemotherapy is increasingly being recognized as a new treatment strategy to improve the outcome of advanced non-small cell lung cancer (NSCLC). However, the optimal maintenance strategy is still controve...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-01-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1756-0500/6/3 |
| _version_ | 1818055560515289088 |
|---|---|
| author | Minami Seigo Kijima Takashi Shiroyama Takayuki Okafuji Kohei Hirashima Tomonori Uchida Junji Imamura Fumio Osaki Tadashi Nakatani Takeshi Ogata Yoshitaka Yamamoto Suguru Namba Yoshinobu Otsuka Tomoyuki Tachibana Isao Komuta Kiyoshi Kawase Ichiro |
| author_facet | Minami Seigo Kijima Takashi Shiroyama Takayuki Okafuji Kohei Hirashima Tomonori Uchida Junji Imamura Fumio Osaki Tadashi Nakatani Takeshi Ogata Yoshitaka Yamamoto Suguru Namba Yoshinobu Otsuka Tomoyuki Tachibana Isao Komuta Kiyoshi Kawase Ichiro |
| author_sort | Minami Seigo |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>In recent years, maintenance chemotherapy is increasingly being recognized as a new treatment strategy to improve the outcome of advanced non-small cell lung cancer (NSCLC). However, the optimal maintenance strategy is still controversial. Gemcitabine is a promising candidate for single-agent maintenance therapy because of little toxicity and good tolerability. We have conducted a randomized phase II study to evaluate the validity of single-agent maintenance chemotherapy of gemcitabine and to compare continuation- and switch-maintenance.</p> <p>Methods</p> <p>Chemonaïve patients with stage IIIB/IV NSCLC were randomly assigned 1:1 to either arm A or B. Patients received paclitaxel (200 mg/m<sup>2</sup>, day 1) plus carboplatin (AUC 6 mg/mL/min, day 1) every 3 weeks in arm A, or gemcitabine (1000 mg/m<sup>2</sup>, days 1 and 8) plus carboplatin (AUC 5 mg/mL/min, day1) every 3 weeks in arm B. Non-progressive patients following 3 cycles of induction chemotherapy received maintenance gemcitabine (1000 mg/m<sup>2</sup>, days 1 and 8) every 3 weeks. (Trial registration: UMIN000008252)</p> <p>Results</p> <p>The study was stopped because of delayed accrual at interim analysis. Of the randomly assigned 50 patients, 49 except for one in arm B were evaluable. Median progression-free survival (PFS) was 4.6 months for arm A <it>vs</it>. 3.5 months for arm B (HR = 1.03; 95% CI, 0.45–2.27; <it>p</it> = 0.95) and median overall survival (OS) was 15.0 months for arm A <it>vs</it>. 14.8 months for arm B (HR = 0.79; 95% CI, 0.40–1.51; <it>p</it> = 0.60), showing no difference between the two arms. The response rate, disease control rate, and the transit rate to maintenance phase were 36.0% (9/25), 64.0% (16/25), and 48% (12/25) for arm A <it>vs</it>. 16.7% (4/24), 50.0% (12/24), and 33% (8/24) for arm B, which were also statistically similar between the two arms (<it>p</it> = 0.13, <it>p</it> = 0.32, and <it>p</it> = 0.30, respectively). Both induction regimens were tolerable, except that more patients experienced peripheral neuropathy in arm A. Toxicities during the maintenance phase were also minimal.</p> <p>Conclusion</p> <p>Survival and overall response were not significantly different between the two arms. Gemcitabine may be well-tolerable and feasible for maintenance therapy.</p> |
| first_indexed | 2024-12-10T12:14:53Z |
| format | Article |
| id | doaj.art-71182083284945f3858ffe491f65f0f8 |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-12-10T12:14:53Z |
| publishDate | 2013-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-71182083284945f3858ffe491f65f0f82022-12-22T01:49:14ZengBMCBMC Research Notes1756-05002013-01-0161310.1186/1756-0500-6-3Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancerMinami SeigoKijima TakashiShiroyama TakayukiOkafuji KoheiHirashima TomonoriUchida JunjiImamura FumioOsaki TadashiNakatani TakeshiOgata YoshitakaYamamoto SuguruNamba YoshinobuOtsuka TomoyukiTachibana IsaoKomuta KiyoshiKawase Ichiro<p>Abstract</p> <p>Background</p> <p>In recent years, maintenance chemotherapy is increasingly being recognized as a new treatment strategy to improve the outcome of advanced non-small cell lung cancer (NSCLC). However, the optimal maintenance strategy is still controversial. Gemcitabine is a promising candidate for single-agent maintenance therapy because of little toxicity and good tolerability. We have conducted a randomized phase II study to evaluate the validity of single-agent maintenance chemotherapy of gemcitabine and to compare continuation- and switch-maintenance.</p> <p>Methods</p> <p>Chemonaïve patients with stage IIIB/IV NSCLC were randomly assigned 1:1 to either arm A or B. Patients received paclitaxel (200 mg/m<sup>2</sup>, day 1) plus carboplatin (AUC 6 mg/mL/min, day 1) every 3 weeks in arm A, or gemcitabine (1000 mg/m<sup>2</sup>, days 1 and 8) plus carboplatin (AUC 5 mg/mL/min, day1) every 3 weeks in arm B. Non-progressive patients following 3 cycles of induction chemotherapy received maintenance gemcitabine (1000 mg/m<sup>2</sup>, days 1 and 8) every 3 weeks. (Trial registration: UMIN000008252)</p> <p>Results</p> <p>The study was stopped because of delayed accrual at interim analysis. Of the randomly assigned 50 patients, 49 except for one in arm B were evaluable. Median progression-free survival (PFS) was 4.6 months for arm A <it>vs</it>. 3.5 months for arm B (HR = 1.03; 95% CI, 0.45–2.27; <it>p</it> = 0.95) and median overall survival (OS) was 15.0 months for arm A <it>vs</it>. 14.8 months for arm B (HR = 0.79; 95% CI, 0.40–1.51; <it>p</it> = 0.60), showing no difference between the two arms. The response rate, disease control rate, and the transit rate to maintenance phase were 36.0% (9/25), 64.0% (16/25), and 48% (12/25) for arm A <it>vs</it>. 16.7% (4/24), 50.0% (12/24), and 33% (8/24) for arm B, which were also statistically similar between the two arms (<it>p</it> = 0.13, <it>p</it> = 0.32, and <it>p</it> = 0.30, respectively). Both induction regimens were tolerable, except that more patients experienced peripheral neuropathy in arm A. Toxicities during the maintenance phase were also minimal.</p> <p>Conclusion</p> <p>Survival and overall response were not significantly different between the two arms. Gemcitabine may be well-tolerable and feasible for maintenance therapy.</p>http://www.biomedcentral.com/1756-0500/6/3CarboplatinGemcitabinePaclitaxelSwitch-maintenanceContinuation-maintenanceNon-small cell lung cancer (NSCLC)Randomized phase II |
| spellingShingle | Minami Seigo Kijima Takashi Shiroyama Takayuki Okafuji Kohei Hirashima Tomonori Uchida Junji Imamura Fumio Osaki Tadashi Nakatani Takeshi Ogata Yoshitaka Yamamoto Suguru Namba Yoshinobu Otsuka Tomoyuki Tachibana Isao Komuta Kiyoshi Kawase Ichiro Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer BMC Research Notes Carboplatin Gemcitabine Paclitaxel Switch-maintenance Continuation-maintenance Non-small cell lung cancer (NSCLC) Randomized phase II |
| title | Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer |
| title_full | Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer |
| title_fullStr | Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer |
| title_full_unstemmed | Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer |
| title_short | Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer |
| title_sort | randomized phase ii trial of paclitaxel and carboplatin followed by gemcitabine switch maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation maintenance therapy in previously untreated advanced non small cell lung cancer |
| topic | Carboplatin Gemcitabine Paclitaxel Switch-maintenance Continuation-maintenance Non-small cell lung cancer (NSCLC) Randomized phase II |
| url | http://www.biomedcentral.com/1756-0500/6/3 |
| work_keys_str_mv | AT minamiseigo randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT kijimatakashi randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT shiroyamatakayuki randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT okafujikohei randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT hirashimatomonori randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT uchidajunji randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT imamurafumio randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT osakitadashi randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT nakatanitakeshi randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT ogatayoshitaka randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT yamamotosuguru randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT nambayoshinobu randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT otsukatomoyuki randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT tachibanaisao randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT komutakiyoshi randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer AT kawaseichiro randomizedphaseiitrialofpaclitaxelandcarboplatinfollowedbygemcitabineswitchmaintenancetherapyversusgemcitabineandcarboplatinfollowedbygemcitabinecontinuationmaintenancetherapyinpreviouslyuntreatedadvancednonsmallcelllungcancer |